CD38介导的代谢重编程促进了瘤中调节性T细胞的稳定性和抑制功能
Ishita Sarkar1,2, Debashree Basak1,2, Puspendu Ghosh1,2
1Division of Cancer Biology and Inflammatory Disorder, IICB-Translational Research Unit of Excellence, CSIR-Indian Institute of Chemical Biology, Kolkata 700032, India.
Science advances
|March 21, 2025
概括
瘤中的调节性T细胞 (Tregs) 通过CD38适应新陈代谢,耗尽NAD+. 用CD38抑制剂向这一轴会破坏Tregs的稳定,增强抗瘤免疫力.
科学领域:
- 免疫学 免疫学 免疫学
- 代谢途径 代谢途径
- 癌症研究 癌症研究
背景情况:
- 调节性T细胞 (Tregs) 在瘤微环境 (TME) 中对免疫抑制至关重要.
- Tregs表现出代谢可塑性,适应营养不良的条件,如低葡萄糖和高乳酸盐.
- 准确的代谢机制,使得Treg适应在TME还没有完全理解.
研究的目的:
- 阐明CD38在Treg代谢适应中的作用.
- 为了研究CD38如何影响尼古丁胺腺因二核酸 (NAD+) 水平和Tregs中的代谢流量.
- 评估针对CD38-NAD+轴增强抗瘤免疫力的治疗潜力.
主要方法:
- 通过细胞检测和小鼠模型,研究了CD38在Treg代谢中的作用.
- 在各种条件下测量Tregs中的NAD+水平和代谢中间体.
- 在患有黑色素瘤的小鼠中使用小分子CD38抑制剂 (YUMM1.7模型).
主要成果:
- CD38被确定为Treg代谢适应的关键调节者,通过耗尽NAD+来调节.
- 抑制CD38将pyruvate从三碳酸 (TCA) 循环中重定向,防止α-甲酸的积累和Treg的不稳定.
- 用尼古丁胺胺单核酸恢复NAD+水平逆转了Treg适应和降低了抑制功能.
- 在黑色素瘤模型中的CD38抑制选择性地破坏了内Tregs的稳定,从而提高了抗瘤免疫力.
结论:
- CD38-NAD+轴对瘤微环境中的Treg代谢适应至关重要.
- 向CD38通过改变其代谢状态来破坏Treg功能.
- 抑制CD38是一种有前途的策略,通过调节Treg活性来增强癌症免疫疗法.
相关概念视频
Tumor Immunotherapy
454
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
454
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K


